Novel Approaches to Enhancing the Diagnosis of Pancreatic Cancer: New Horizons and Emerging Technologies

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 15, 2014
Expiration Date: December 15, 2015

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Pancreatic cancer is a rare disease that is often diagnosed at advanced stages, resulting in a 5-year survival rate of less than 5%. To address this issue, significant research is ongoing to identify novel techniques and approaches that will support earlier diagnosis of this fatal disease. In this discussion, two leading pancreatic cancer researchers discuss new and emerging serological tests that are being investigated for pancreatic cancer, as well as novel diagnostic approaches for cystic lesions of the pancreas that will support improved patient stratification and treatment.

Target Audience

This activity is designed for oncologists, pharmacists, and associated multidisciplinary clinical specialists who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify genetic syndromes which have been associated with an increased risk of developing pancreatic cancer

  • Describe new and emerging serological tests which are being investigated for efficacy in earlier diagnosis of pancreatic cancer, focusing on those methods which incorporate screening for circulating tumor cells and circulating epithelial cells

  • Summarize current state of knowledge concerning cystic lesions of the pancreas, focusing on the role of novel diagnostic approaches in developing therapeutic strategies for patients with pancreatic cancer

Agenda

Anil K. Rustgi, MD – Moderator
Koushik K. Das, MD – Panelist

Instructions for Participation and Credit

This activity is eligible for credit through December 15, 2015. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Anil K. Rustgi, MD
T. Grier Miller Professor of Medicine and Genetics
Chief, Division of Gastroenterology
University of Pennsylvania, School of Medicine
Philadelphia, Pennsylvania

Dr. Anil Rustgi received his medical degree from Duke University Medical School and completed his medical internship and residency at Beth Israel Hospital of Harvard University, and also served as chief medical resident. He then completed his gastroenterology fellowship at Massachusetts General Hospital (MGH) of Harvard Medical School. Dr. Rustgi is the chief of gastroenterology and the T. Grier Miller Professor of Medicine and Genetics, as well as director of the Digestive Diseases and Liver Clinical Center at the University of Pennsylvania.

Dr. Rustgi is a diplomate in gastroenterology, American Board of Internal Medicine. He is on the scientific advisory board of the National Pancreas Foundation, Caring for Carcinoid Foundation, and PanCAN, and is past-president of the American Gastroenterology Association. Dr. Rustgi is a reviewer for numerous peer-reviewed journals including Science, Cancer Cell, Journal of Clinical Investigation, New England Journal of Medicine, Gastroenterology, Annals of Internal Medicine, Lancet, American Journal of Medicine, and Cancer Research, just to name a few. In addition, he is associate editor of Cancer Research, Cancer Biology & Therapy, and GI Cancer. His primary research interest is in GI cancer biology and genetics related to oral-esophageal cancer, pancreatic cancer, and colon cancer, with a particular focus in tumor microenvironment.

Koushik K. Das, MD
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Koushik Das received his medical degree from Columbia University College of Physicians and Surgeons in New York City, and completed his internship and residency in medicine at Massachusetts General Hospital, Boston. He is currently a fellow in gastroenterology at the University of Pennsylvania, Philadelphia, where he will also complete his advanced endoscopy fellowship.

Dr. Das is American Board of Internal Medicine certified. He has held memberships in the American Society for Gastrointestinal Endoscopy, American Association for the Study of Liver Diseases, American College of Physicians, American Medical Association, and the Massachusetts Medical Society. Dr. Das has published several abstracts and original papers on intraductal papillary mucinous neoplasm (IPMN) and intestinal metaplasia.

Accreditation

MediCom WOrldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-14-042-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Anil Rustgi and Dr. Koushik Das have disclosed no relevant financial relationships.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Rustgi and Dr. Das have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Rustgi and Dr. Das have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@partnersinpancreaticcancer.com.

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Celgene Corporation and Aduro BioTech.

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved